Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: A multi-institutional study.
The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Inadequate antimicrobial treatment is an independent determinant of hospital mortality, and fungal bloodstream infections are among the types of infection with the highest rates of inappropriate initial treatment. Because of significant potential for reducing high mortality rates, we sought to assess the impact of delayed treatment across multiple study sites. The goals our analyses were to establish the frequency and duration of delayed antifungal treatment and to evaluate the relationship between treatment delay and mortality. METHODS: We conducted a retrospective cohort study of patients with candidemia from 4 medical centers who were prescribed fluconazole. Time to initiation of fluconazole therapy was calculated by subtracting the date on which fluconazole therapy was initiated from the culture date of the first blood sample positive for yeast. RESULTS: A total of 230 patients (51% male; mean age +/- standard deviation, 56 +/- 17 years) were identified; 192 of these had not been given prior treatment with fluconazole. Patients most commonly had nonsurgical hospital admission (162 patients [70%]) with a central line catheter (193 [84%]), diabetes (68 [30%]), or cancer (54 [24%]). Candida species causing infection included Candida albicans (129 patients [56%]), Candida glabrata (38 [16%]), Candida parapsilosis (25 [11%]), or Candida tropicalis (15 [7%]). The number of days to the initiation of antifungal treatment was 0 (92 patients [40%]), 1 (38 [17%]), 2 (33 [14%]) or > or = 3 (29 [12%]). Mortality rates were lowest for patients who began therapy on day 0 (14 patients [15%]) followed by patients who began on day 1 (9 [24%]), day 2 (12 [37%]), or day > or = 3 (12 [41%]) (P = .0009 for trend). Multivariate logistic regression was used to calculate independent predictors of mortality, which include increased time until fluconazole initiation (odds ratio, 1.42; P < .05) and Acute Physiology and Chronic Health Evaluation II score (1-point increments; odds ratio, 1.13; P < .05). CONCLUSION: A delay in the initiation of fluconazole therapy in hospitalized patients with candidemia significantly impacted mortality. New methods to avoid delays in appropriate antifungal therapy, such as rapid diagnostic tests or identification of unique risk factors, are needed.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The mortality reduction associated with early antimicrobials appears strongest in patients with septic shock, where studies have reported a strong association between time to antibiotics and death in patients with septic shock but weaker associations in patients without septic shock (98,109,110).”
From Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock 2021. (2021) · cites this paper as [109]
In the citing paper
“Blood cultures take an average of 2–3 days to grow Candida, or longer depending on the species.”
From Epidemiology of Invasive Candidiasis (2024) · cites this paper as [135]
In the citing paper
“Attributable mortality from IC remains high and increases with delays in treatment.”
From Epidemiology of Invasive Candidiasis (2024) · cites this paper as [135]
In the citing paper
“Some observational studies suggested that prompt initiation of appropriate empiric antifungal therapy may be associated with a reduction in mortality, however these studies do not prove a causal relationship between antifungal therapy and outcome, nor do they clarify the role of timing of treatment, and some other studies have failed to show this association [167, 171–173].”
From Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021 (2021) · cites this paper as [171]
In the citing paper
“Multivariate analysis in this study also provided a strong association between delay in therapy and mortality.”
From Fungal Sepsis: Optimizing Antifungal Therapy in the Critical Care Setting (2011) · cites this paper as [46]
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Wisplinghoff, H., Bischoff, T., Tallent, S. M., Seifert, H., Wenzel, R. P., & Edmond, M. B. (2004) · Clinical Infectious Diseases · doi:10.1086/421946 · Cited by 4,496 · cited 11×
“By contrast, gram-positive bacteria, such as coagulase-negative staphylococci, S. aureus, and Enterococcus species, account for 60% of all BSIs [16].”
BackgroundInfluentialIbrahim, E. H., Sherman, G., Ward, S., Fraser, V. J., & Kollef, M. H. (2000) · Chest · doi:10.1378/chest.118.1.146 · Cited by 1,779 · cited 2×
“of inappropriate initial treatment [6].”
BackgroundMorrell, M., Fraser, V. J., & Kollef, M. H. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.9.3640-3645.2005 · Cited by 1,286 · cited 5×
“Delaying antifungal therapy appears to be a common practice, and the impact on mortality may be significant [8, 10].”
BackgroundResultInfluentialAttributable Mortality of Nosocomial Candidemia, Revisited
Gudlaugsson, O., Gillespie, S., Lee, K., Berg, J. V., Hu, J., Messer, S., Herwaldt, L., Pfaller, M., & Diekema, D. (2003) · Clinical Infectious Diseases · doi:10.1086/378745 · Cited by 1,140 · cited 2×
“Attributable mortality rates of 49% were also shown among patients with candidemia, compared with uninfected control subjects matched for age, sex, date of hospital admission, underlying diseases, length of time at risk, and type of surgical procedure [5].”
BackgroundPfaller, M. A., Diekema, D. J., Jones, R. N., Sader, H. S., Fluit, A. C., Hollis, R. J., Messer, S. A., & The SENTRY Participant Group (2001) · Journal of Clinical Microbiology · doi:10.1128/jcm.39.9.3254-3259.2001 · Cited by 521 · cited 1×
“[1].”
Morgan, J., Meltzer, M. I., Plikaytis, B. D., Sofair, A. N., Huie-White, S., Wilcox, S., Harrison, L. H., Seaberg, E. C., Hajjeh, R. A., & Teutsch, S. M. (2005) · Infection Control & Hospital Epidemiology · doi:10.1086/502581 · Cited by 437 · cited 2×
“attributable mortality remains 19%–49% [2, 5].”
Pfaller, M. A., Jones, R. N., Messer, S. A., Edmond, M. B., & Wenzel, R. P. (1998) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/s0732-8893(97)00240-x · Cited by 331 · cited 10×
“By contrast, gram-positive bacteria, such as coagulase-negative staphylococci, S. aureus, and Enterococcus species, account for 60% of all BSIs [16].”
BackgroundInfluentialThe Impact of Candidemia on Length of Hospital Stay, Outcome, and Overall Cost of Illness
Rentz, A. M., Halpern, M. T., & Bowden, R. (1998) · Clinical Infectious Diseases · doi:10.1086/514955 · Cited by 310 · cited 1×
“of 8 cases per 100,000 population [2–4].”
Leinberger, D. M., Schumacher, U., Autenrieth, I. B., & Bachmann, T. T. (2005) · Journal of Clinical Microbiology · doi:10.1128/jcm.43.10.4943-4953.2005 · Cited by 155 · cited 1×
“Development of nonculture methods for the rapid diagnosis of candidemia in patients with BSI may also significantly improve the ability to quickly prescribe appropriate antifungal therapy [19, 20].”
Epidemiology and Prognostic Determinants of Bloodstream Infections in Surgical Intensive Care
Harbarth, S. (2002) · Archives of Surgery · doi:10.1001/archsurg.137.12.1353 · Cited by 135
Cited by
Items 201–300 of 1,000
Lau, A. F., Kabir, M., Chen, S. C.-A., Playford, E. G., Marriott, D. J., Jones, M., Lipman, J., McBryde, E., Gottlieb, T., Cheung, W., et al. (2015) · Journal of Clinical Microbiology · doi:10.1128/jcm.03239-14 · Cited by 74
Invasive Fungal Infections in the Intensive Care Unit
Ostrosky-Zeichner, L., & Al-Obaidi, M. (2017) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2017.05.005 · Cited by 76
Recent advances in the microbiological diagnosis of bloodstream infections
Florio, W., Morici, P., Ghelardi, E., Barnini, S., & Lupetti, A. (2017) · Critical Reviews in Microbiology · doi:10.1080/1040841x.2017.1407745 · Cited by 82
“…in the diagnosis of candidemia, since sensitivity for detection of Candida spp. by BC is only approximately 50% (Clancy and Nguyen 2013), and it has been shown that initiation of appropriate antifungal treatment in less than 12 h can significantly reduce the mortality rate (Garey et al. 2006).”
BackgroundShah, D. N., Yau, R., Weston, J., Lasco, T. M., Salazar, M., Palmer, H. R., & Garey, K. W. (2011) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkr244 · Cited by 75
Self-citationAguado, J. M., Ruíz-Camps, I., Muñóz, P., Mensa, J., Almirante, B., Vázquez, L., Rovira, M., Martín‐Dávila, P., Moreno, A., Álvarez-Lerma, F., et al. (2011) · Enfermedades Infecciosas y Microbiología Clínica · doi:10.1016/j.eimc.2011.01.008 · Cited by 94
Pauw, B. E. D. (2011) · Mediterranean Journal of Hematology and Infectious Diseases · doi:10.4084/mjhid.2011.001 · Cited by 84
Yang, S.-P., Chen, Y.-Y., Hsu, H., Wang, F., Chen, L.-Y., & Fung, C.-P. (2013) · BMC Infectious Diseases · doi:10.1186/1471-2334-13-10 · Cited by 84
“Early treatment had been documented to improve the outcome of candidemia, [35,36] although early diagnostic tools are still inadequate.”
BackgroundPletz, M. W., Wellinghausen, N., & Welte, T. (2011) · Intensive Care Medicine · doi:10.1007/s00134-011-2245-x · Cited by 81
“significantly increases mortality in patients with fungal infections [13–15].”
BackgroundHope, W. W., Petraitis, V., Petraitiene, R., Aghamolla, T., Bacher, J., & Walsh, T. J. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00673-10 · Cited by 73
“Both clinical and preclinical data increasingly attest to the importance of early antimicrobial therapy for achieving optimal clinical outcomes (4, 5, 8, 11, 15, 16).”
BackgroundCurrent Status and Future Perspectives on Molecular and Serological Methods in Diagnostic Mycology
Lau, A. F., Chen, W., Sleiman, S., & Sorrell, T. C. (2009) · Future Microbiology · doi:10.2217/fmb.09.70 · Cited by 78
“Early diagnosis is important as delayed institution of antifungal therapy leads to poor clinical outcomes [6,7].”
BackgroundGoff, D. A., Jankowski, C., & Tenover, F. C. (2012) · Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/j.1875-9114.2012.01137.x · Cited by 73
Candidemia in children: Epidemiology, prevention and management
Mantadakis, E., Pana, Z. D., & Zaoutis, T. E. (2018) · Mycoses · doi:10.1111/myc.12792 · Cited by 77
Therapy and outcome of Candida glabrata versus Candida albicans bloodstream infection
Klevay, M. J., Ernst, E. J., Hollanbaugh, J. L., Miller, J. G., Pfaller, M. A., & Diekema, D. J. (2008) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2007.10.001 · Cited by 73
“Garey et al. (2006) have shown that mortality increases incrementally with each day of a delay in”
BackgroundInfluentialThe Importance of Early Treatment With Doxycycline in Human Ehrlichiosis
Hamburg, B. J., Storch, G. A., Micek, S. T., & Kollef, M. H. (2008) · Medicine · doi:10.1097/md.0b013e318168da1d · Cited by 74
Invasive Mycoses: Strategies for Effective Management
Kontoyiannis, D. P. (2011) · The American Journal of Medicine · doi:10.1016/j.amjmed.2011.10.009 · Cited by 80
Changing pattern of fungal infection in burn patients
Sarabahi, S., Tiwari, V. K., Arora, S., Capoor, M. R., & Pandey, A. (2011) · Burns · doi:10.1016/j.burns.2011.09.013 · Cited by 75
“[21] Garey KW, Rege M, Pai MP, Mingo DE, Suda KJ, Turpin RS, et al.”
BackgroundOccurrence, presentation and treatment of candidemia
Mikulska, M., Del Bono, V., Ratto, S., & Viscoli, C. (2012) · Expert Review of Clinical Immunology · doi:10.1586/eci.12.52 · Cited by 71
Invasive fungal infections in acute leukemia
Bhatt, V. R., Viola, G. M., & Ferrajoli, A. (2011) · Therapeutic Advances in Hematology · doi:10.1177/2040620711410098 · Cited by 71
“Early initiation of antifungal therapy is crucial for AL patients because delay is associated with increased mortality due to candidemia [Taur et al. 2010; Garey et al. 2006; Morrell et al. 2005] and due to invasive mold infection [Chamilos et al. 2008; von Eiff et al. 1995].”
BackgroundKollef, M. H., Napolitano, L. M., Solomkin, J. S., Wunderink, R. G., Bae, I., Fowler, V. G., Balk, R. A., Stevens, D. L., Rahal, J. J., Shorr, A. F., et al. (2008) · Clinical Infectious Diseases · doi:10.1086/590937 · Cited by 69
“[91] reviewed 230 cases of candidemia at 4 different centers.”
BackgroundClinical impact of time to positivity for Candida species on mortality in patients with candidaemia
Kim, S.-H., Yoon, Y. K., Kim, M. J., & Sohn, J. W. (2013) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkt256 · Cited by 68
Canadian Clinical Practice Guidelines for Invasive Candidiasis in Adults
Bow, E. J., Evans, G., Fuller, J., Laverdière, M., Rotstein, C., Rennie, R., Shafran, S. D., Sheppard, D., Carle, S., Phillips, P., et al. (2010) · Canadian Journal of Infectious Diseases and Medical Microbiology · doi:10.1155/2010/357076 · Cited by 70
Pharmacologic and clinical evaluation of posaconazole
Moore, J. N., Healy, J., & Kraft, W. K. (2015) · Expert Review of Clinical Pharmacology · doi:10.1586/17512433.2015.1034689 · Cited by 77
“Prophylactic treatment is often advantageous, as delayed antifungal treatment has been shown to increase mortality rates [1,2].”
Invasive candidiasis: A review of nonculture-based laboratory diagnostic methods
Ahmad, S., & Khan, Z. (2012) · Indian Journal of Medical Microbiology · doi:10.4103/0255-0857.99482 · Cited by 67
González de Molina, F. J., León, C., Ruiz-Santana, S., Saavedra, P., & the CAVA I Study Group (2012) · Critical Care · doi:10.1186/cc11388 · Cited by 66
“An early start of appropriate antifungal therapy (within the critical time-frame of the first 24 to 48 hours) is crucial for the reduction of bloodstream infection-related mortality [24,25].”
BackgroundJensen, R. H., & Arendrup, M. C. (2011) · Journal of Clinical Microbiology · doi:10.1128/jcm.02071-10 · Cited by 68
PARK, D.-H., Park, K. W., Park, J. M., PARK, H.-H., Chae, H., Lim, J., Oh, E., Kim, Y., Park, Y. J., & HAN, K. (2011) · International Journal of Laboratory Hematology · doi:10.1111/j.1751-553x.2011.01298.x · Cited by 68
“The condition is associated with high morbidity and mortality, and the prompt diagnosis and appropriate initiation of antifungal therapy are quite important (Garey et al., 2006; Kludze-Forson et al., 2010).”
BackgroundDou, Y., Du, J., Liu, H., & Shong, X.-D. (2013) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2013.04.023 · Cited by 68
Opportunistic fungal infections in the Asia-Pacific region
Slavin, M. A., & Chakrabarti, A. (2012) · Medical Mycology · doi:10.3109/13693786.2011.602989 · Cited by 68
B, V. H., Bruynseels, P., Bensaid, M., Boekhout, T., Baere, T. D., Surmont, I., & Mertens, A. (2011) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-011-1383-y · Cited by 73
Locke, J. B., Almaguer, A. L., Zuill, D. E., & Bartizal, K. (2016) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00620-16 · Cited by 64
“Given that early therapeutic intervention/drug exposure is critical for the treatment fungal infections (9, 10), this front-loading dosing paradigm could be beneficial in improving efficacy over smaller daily doses (as has been observed with antibacterials) (11, 12) and could also have advantages in resistance prevent…”
BackgroundTolerability profile of the current antifungal armoury
Mourad, A., & Perfect, J. R. (2018) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkx446 · Cited by 62
Castanheira, M., Messer, S. A., Jones, R. N., Farrell, D. J., & Pfaller, M. A. (2014) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2014.06.007 · Cited by 66
Extracellular DNA release confers heterogeneity in Candida albicans biofilm formation
Rajendran, R., Sherry, L., Lappin, D. F., Nile, C. J., Smith, K., Williams, C., Munro, C. A., & Ramage, G. (2014) · BMC Microbiology · doi:10.1186/s12866-014-0303-6 · Cited by 66
Heil, E. L., Daniels, L. M., Long, D. M., Rodino, K. G., Weber, D. J., & Miller, M. B. (2012) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp110604 · Cited by 66
“Delays in initiating antifungal therapy in patients with candidemia are associated with increased mortality.(4) Traditional laboratory methods of identifying Candida species can take up to five days, precluding the early use of less-expensive, targeted therapy.”
BackgroundRecommendations for the treatment of established fungal infections
Thursky, K., Playford, E. G., Seymour, J. F., Sorrell, T. C., Ellis, D. H., Guy, S., Gilroy, N. M., Chu, J., & Shaw, D. (2008) · Internal Medicine Journal · doi:10.1111/j.1445-5994.2008.01725.x · Cited by 68
Ellis, M., Al-Ramadi, B., Bernsen, R., Kristensen, J., Alizadeh, H., & Hedstrom, U. (2009) · Journal of Medical Microbiology · doi:10.1099/jmm.0.006452-0 · Cited by 61
“Such an approach would extend the interval between any first positive M test and the diagnosis of IC by a median of 4 days and hence identify more patients at an earlier stage of IC, given the day-to-day variability in positive results, and would hence improve survival as earlier treatment could be instigated (Garey e…”
BackgroundGuinea, J., Recio, S., Escribano, P., Torres-Narbona, M., Peláez, T., Sánchez‐Carrillo, C., Rodríguez‐Créixems, M., & Bouza, E. (2010) · Journal of Clinical Microbiology · doi:10.1128/jcm.02321-09 · Cited by 71
“The mortality rate of fungemia remains high (30%) and is clearly correlated with delayed initiation of effective antifungal therapy (11, 17).”
BackgroundEmpiric Antimicrobial Therapy in Severe Sepsis and Septic Shock: Optimizing Pathogen Clearance
Liang, S. Y., & Kumar, A. (2015) · Current Infectious Disease Reports · doi:10.1007/s11908-015-0493-6 · Cited by 76
Garey, K. W., Pai, M. P., Suda, K. J., Turpin, R. S., Rege, M. D., Mingo, D. E., & Bearden, D. T. (2007) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.1365 · Cited by 64
“We did not assess outcomes in this study as we were not able to perform susceptibility testing on the organisms and many patients had a delay starting antifungal therapy, another important predictor of poor outcomes.(32) Likewise, in this retrospective study, we were unable to assess the reasons for inappropriate fluc…”
ResultSelf-citationClancy, C. J., Nguyen, M.-L., Cheng, S., Huang, H., Fan, G., Jaber, R. A., Wingard, J. R., Cline, C., & Nguyen, M. H. (2008) · Journal of Clinical Microbiology · doi:10.1128/jcm.02018-07 · Cited by 62
“Such findings are consistent with the fact that blood cultures are often not positive until relatively late in the course of disease (8, 17, 18).”
BackgroundFactors related to outcome of bloodstream infections due to Candida parapsilosis complex
Barchiesi, F., Orsetti, E., Osimani, P., Catassi, C., Santelli, F., & Manso, E. (2016) · BMC Infectious Diseases · doi:10.1186/s12879-016-1704-y · Cited by 69
The value of amphotericin B in the treatment of invasive fungal infections
Klepser, M. E. (2010) · Journal of Critical Care · doi:10.1016/j.jcrc.2010.08.005 · Cited by 77
Optimizing antifungal choice and administration
Andes, D. (2013) · Current Medical Research and Opinion · doi:10.1185/03007995.2012.761135 · Cited by 63
van der Elst, K. C. M., Span, L. F. R., van Hateren, K., Vermeulen, K. M., van der Werf, T. S., Greijdanus, B., Kosterink, J. G. W., Uges, D. R. A., & Alffenaar, J. C. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00707-13 · Cited by 65
Pondérand, L., Pavèse, P., Maubon, D., Giraudon, E., Girard, T., Landelle, C., Maurin, M., & Caspar, Y. (2020) · Annals of Clinical Microbiology and Antimicrobials · doi:10.1186/s12941-020-00403-w · Cited by 63
Fungal Sepsis: Optimizing Antifungal Therapy in the Critical Care Setting
Lepak, A., & Andes, D. (2011) · Critical Care Clinics · doi:10.1016/j.ccc.2010.11.001 · Cited by 62
Shorr, A. F., Gupta, V., Sun, X., Johannes, R. S., Spalding, J., & Tabak, Y. P. (2009) · Critical Care Medicine · doi:10.1097/ccm.0b013e3181a0f95d · Cited by 62
“7) Unadjusted median (Q1, Q3) 9 (6, 16) 8 (5, 13) 6 (4, 9) 8 (5, 14) 8 (5, 13) Adjusted attributable LOS (95% CI) 4.”
Amphotericin B in the Era of New Antifungals: Where Will It Stand?
Akinosoglou, K., Rigopoulos, E. A., Papageorgiou, D., Schinas, G., Polyzou, E., Dimopoulou, E., Gogos, C. A., & Dimοpoulos, G. (2024) · Journal of Fungi · doi:10.3390/jof10040278 · Cited by 68
“Similarly, Garey et al. showed that increased time until fluconazole initiation was an independent predictor of mortality (OR, 1.42; p < 0.05) in a retrospective study of 230 hospitalized patients with candidemia [6].”
BackgroundInfluentialImproving the management of candidemia through antimicrobial stewardship interventions
Reed, E. E., West, J. E., Keating, E. A., Pancholi, P., Balada-Llasat, J.-M., Mangino, J. E., Bauer, K. A. A., & Goff, D. A. (2013) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2013.11.012 · Cited by 66
Approach to the Diagnosis of Invasive Aspergillosis and Candidiasis
Wheat, L. J. (2009) · Clinics in Chest Medicine · doi:10.1016/j.ccm.2009.02.012 · Cited by 65
Low Caspofungin Exposure in Patients in Intensive Care Units
van der Elst, K. C. M., Veringa, A., Zijlstra, J. G., Beishuizen, A., Klont, R., Brummelhuis-Visser, P., Uges, D. R. A., Touw, D. J., Kosterink, J. G. W., van der Werf, T. S., et al. (2016) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01582-16 · Cited by 64
“Then, the strategy would be to acquire at least adequate exposure to cover susceptible Candida species, since a delay in appropriate antifungal therapy affects mortality (10).”
BackgroundInfluentialFortun, J., Meije, Y., Buitrago, M. J., Gago, S., Bernal-Martinez, L., Peman, J., Perez, M., Gomez-G Pedrosa, E., Madrid, N., Pintado, V., et al. (2014) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dku225 · Cited by 61
Schreiber, J., Nierhaus, A., Braune, S. A., de Heer, G., & Kluge, S. (2013) · Medizinische Klinik - Intensivmedizin und Notfallmedizin · doi:10.1007/s00063-013-0227-1 · Cited by 69
Candida Bloodstream Infections: Changes in Epidemiology and Increase in Drug Resistance
Kotey, F. C. N., Dayie, N. T. K. D., Tetteh‐Quarcoo, P. B., & Donkor, E. S. (2021) · Infectious Diseases Research and Treatment · doi:10.1177/11786337211026927 · Cited by 77
Pfaller, M. A., Boyken, L., Hollis, R. J., Kroeger, J., Messer, S. A., Tendolkar, S., & Diekema, D. J. (2011) · Journal of Clinical Microbiology · doi:10.1128/jcm.02161-10 · Cited by 61
“Given the facts that a shorter incubation period is more efficient and practical for use in the clinical laboratory (16, 36) and that research has shown that early/ correct antifungal treatment has a positive effect on outcomes for patients with candidemia (5, 6, 12, 19, 20, 23, 27, 29, 33, 53), the CLSI has determine…”
MethodT2Candida Provides Rapid and Accurate Species Identification in Pediatric Cases of Candidemia
Hamula, C. L. A., Hughes, K., Fisher, B. T., Zaoutis, T. E., Singh, I. R., & Velegraki, A. (2016) · American Journal of Clinical Pathology · doi:10.1093/ajcp/aqw063 · Cited by 61
“Candidemia prolongs hospital length of stay, increases costs, and has an attributable mortality of 10%.(1) Prior studies have suggested that prolongation of the time from onset of signs of infection until initiation of antifungal therapy is associated with increased mortality.”
BackgroundCurrent diagnostic approaches to invasive candidiasis in critical care settings
Pemán, J., & Zaragoza, R. (2010) · Mycoses · doi:10.1111/j.1439-0507.2009.01732.x · Cited by 68
Bench-to-bedside review: Therapeutic management of invasive candidiasis in the intensive care unit
Bassetti, M., Mikulska, M., & Viscoli, C. (2010) · Critical Care · doi:10.1186/cc9239 · Cited by 57
“All these eff orts are aimed at reducing morbidity and mortality by starting treatment as early as possible, given the evidence that a delay in antifungal prescription increases mortality rates signifi cantly in candidemia [ 13 ,14].”
BackgroundEarly Antimicrobial Therapy in Severe Sepsis and Septic Shock
Kumar, A. (2010) · Current Infectious Disease Reports · doi:10.1007/s11908-010-0128-x · Cited by 67
Garvey, M., Meade, E., & Rowan, N. J. (2022) · The Science of The Total Environment · doi:10.1016/j.scitotenv.2022.158284 · Cited by 64
Antimicrobial Therapy for Life-threatening Infections: Speed is Life
Funk, D. J., & Kumar, A. (2010) · Critical Care Clinics · doi:10.1016/j.ccc.2010.09.008 · Cited by 70
Rosenvinge, F. S., Dzajic, E., Knudsen, E., Malig, S., Andersen, L. B., Løvig, A., Arendrup, M. C., Jensen, T. G., Gahrn‐Hansen, B., & Kemp, M. (2012) · Mycoses · doi:10.1111/myc.12000 · Cited by 63
Arendrup, M. C., Fisher, B. T., & Zaoutis, T. E. (2009) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2009.02909.x · Cited by 67
Aittakorpi, A., Kuusela, P., Koukila-Kähkölä, P., Vaara, M., Petrou, M. A., Gant, V. A., & Mäki, M. (2012) · Journal of Clinical Microbiology · doi:10.1128/jcm.01461-12 · Cited by 62
“BSI remains a life-threatening condition, and early initiation of effective antimicrobial therapy at least for bacterial infection is a major predictor of outcome (14, 20, 25).”
BackgroundZhao, Y. J., Khoo, A. L., Tan, G., Teng, M., Tee, C., Tan, B. H., Ong, B., Lim, B. P., & Chai, L. Y. A. (2015) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01985-15 · Cited by 62
“Prophylactic strategies are central to the containment of IFIs (4, 5), because early diagnosis of disease, which is critical for optimizing treatment outcomes, remains elusive despite recent advances in diagnostic techniques (6).”
BackgroundDecker, S., Sigl, A., Grumaz, C., Stevens, P., Vainshtein, Y., Zimmermann, S., Weigand, M. A., Hofer, S., Sohn, K., & Brenner, T. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18081796 · Cited by 61
“Accordingly, a fungal infection needs to be detected as early as possible in order to initiate a targeted life-saving antifungal therapy, since delayed initiation of appropriate antifungal therapy has been shown to increase morbidity and mortality [23,24,52,53].”
BackgroundPlayford, E. G., Lipman, J., Kabir, M., McBryde, E. S., Nimmo, G. R., Lau, A. F., & Sorrell, T. C. (2009) · Intensive Care Medicine · doi:10.1007/s00134-009-1619-9 · Cited by 64
“Observational studies suggest that survivability improves when antifungals are administered within 12–24 h of the first positive blood culture [2, 3].”
BackgroundSheppard, D. C., Locas, M., Restieri, C., & Laverdière, M. (2008) · Journal of Clinical Microbiology · doi:10.1128/jcm.01113-08 · Cited by 78
“Recent evidence has suggested that early institution of appropriate antifungal therapy is a critical factor in improving outcomes during bloodstream infections with Candida species (2, 4, 5).”
BackgroundSynergy of the antibiotic colistin with echinocandin antifungals in Candida species
Zeidler, U., Bougnoux, M.-E., Lupan, A., Helynck, O., Doyen, A., Garcia, Z., Sertour, N., Clavaud, C., Munier-Lehmann, H., Saveanu, C., et al. (2013) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dks538 · Cited by 58
Wiederhold, N. P., Najvar, L. K., Bocanegra, R., Kirkpatrick, W. R., Patterson, T. F., & Thornton, C. R. (2013) · Journal of Clinical Microbiology · doi:10.1128/jcm.02142-12 · Cited by 58
Hsu, D. I., Nguyen, M., Nguyen, L., Law, A. V., & Wong‐Beringer, A. (2010) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkq216 · Cited by 62
Azole‐resistant Candida spp. – emerging pathogens?
Tobudic, S., Kratzer, C., & Presterl, E. (2012) · Mycoses · doi:10.1111/j.1439-0507.2011.02146.x · Cited by 56
Arendrup, M. C., Rodriguez-Tudela, J.-L., Park, S., Garcia-Effron, G., Delmas, G., Cuenca-Estrella, M., Gomez-Lopez, A., & Perlin, D. S. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01364-10 · Cited by 57
Diagnosis and Treatment of Candidemia in the Intensive Care Unit
Bassetti, M., Giacobbe, D. R., Vena, A., & Wolff, M. (2019) · Seminars in Respiratory and Critical Care Medicine · doi:10.1055/s-0039-1693704 · Cited by 72
Kobayashi, T., Marra, A. R., Schweizer, M. L., Eyck, P. T., Wu, C., Alzunitan, M. A., Salinas, J. L., Siegel, M., Farmakiotis, D., Auwaerter, P. G., et al. (2020) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofaa270 · Cited by 59
Epidemiology of invasive candidiasis in a surgical intensive care unit: an observational study
Aguilar, G., Delgado, C., Corrales, I., Izquierdo, A. C., Gracia, E., Moreno, T., Romero, E., Ferrando, C., Carbonell, J., Borrás, R., et al. (2015) · BMC Research Notes · doi:10.1186/s13104-015-1458-4 · Cited by 77
“In IAC, as in candidemias, the delay in the initiation of antifungal therapy is a major determinant of clinical outcome [23, 24].”
BackgroundCandidaInfections and Their Prevention
Kabir, M. A., & Ahmad, Z. (2012) · ISRN Preventive Medicine · doi:10.5402/2013/763628 · Cited by 71
The Economic Impact of Rapid Candida Species Identification by T2Candida Among High-Risk Patients
Bilir, S. P., Ferrufino, C. P., Pfaller, M. A., & Munakata, J. (2015) · Future Microbiology · doi:10.2217/fmb.15.29 · Cited by 58
Ericson, E.-L., Klingspor, L., Ullberg, M., & Özenci, V. (2012) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2012.02.020 · Cited by 55
Invasive Fungal Infections in the ICU
Shoham, S., & Marwaha, S. (2009) · Journal of Intensive Care Medicine · doi:10.1177/0885066609355262 · Cited by 63
Diagnostic Performance of T2Candida Among ICU Patients With Risk Factors for Invasive Candidiasis
Arendrup, M. C., Andersen, J. S., Holten, M., Krarup, K. B., Reiter, N., Schierbeck, J., & Helleberg, M. (2019) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofz136 · Cited by 56
“A 2-day delay in antifungal therapy has been associated with more than a doubling of the mortality rate in several [15, 16] but not all studies [2, 17, 18].”
BackgroundWhite, S., Schmidt, R. L., Walker, B. S., & Hanson, K. E. (2020) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd009833.pub2 · Cited by 72
Chen, P., Chuang, Y., Wang, J., Sheng, W., Yu, C., Chu, C.-C., Hsueh, P., Chang, S., & Chen, Y. (2012) · Journal of Microbiology Immunology and Infection · doi:10.1016/j.jmii.2012.08.025 · Cited by 54
“This finding was concordant to two recent reports(37,38) but differed from others.(39,40) As to this discrepancy, severity of illness, such as the Acute Physiology and Chronic Health Evaluation (APACHE) II score, should be taken into consideration.”
ResultTumbarello, M., Sanguinetti, M., Trecarichi, E. M., La Sorda, M., Rossi, M., de Carolis, E., de Gaetano Donati, K., Fadda, G., Cauda, R., & Posteraro, B. (2008) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkn381 · Cited by 53
Mortality-associated factors of candidemia: a multi-center prospective cohort in Turkey
Kutlu, M., Kutlu, S. S., Çavuş, S. A., Öztürk, Ş. B., Tasbakan, M. I., Özhak, B., Kaya, O., Kutsoylu, O. Ö. E., Akar, Ş. Ş., Turhan, Ö., et al. (2022) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-021-04394-0 · Cited by 54
Spontaneous fungal peritonitis: Epidemiology, current evidence and future prospective
Fiore, M., & Leone, S. (2016) · World Journal of Gastroenterology · doi:10.3748/wjg.v22.i34.7742 · Cited by 53
Diagnostic challenges and recent advances in the early management of invasive fungal infections
Chandrasekar, P. H. (2010) · European Journal Of Haematology · doi:10.1111/j.1600-0609.2009.01391.x · Cited by 55
the study group Candida albicans Germ Tube Antibody Detection in Critically Ill Patients (CAGTAUCI), Pemán, J., Zaragoza, R., Quindós, G., Alkorta, M., Cuétara, M. S., Camarena, J. J., Ramírez, P., Giménez, M. J., Martín‐Mazuelos, E., et al. (2011) · BMC Infectious Diseases · doi:10.1186/1471-2334-11-60 · Cited by 55
“Poor outcomes are associated with the difficulty in establishing the microbiological diagnosis at an early stage of IC (blood culture results are positive in only 50% and the antigen or antibody detection also show low sensitivity rates at the present time) [2] and the delay in receiving antifungal treatment [8,9].”
BackgroundRosa, F. G. D., Corcione, S., Filippini, C., Raviolo, S., Fossati, L., Montrucchio, C., Aldieri, C., Petrolo, A., Cavallo, R., & Perri, G. D. (2015) · PLoS ONE · doi:10.1371/journal.pone.0125149 · Cited by 56
“In our analysis only 28% of our patients received early antifungal therapy, mostly with fluconazole, highlighting that a delay in treatment for fungal BSI is very frequent in IMWs and is associated with higher risk of mortality, as previously reported in different studies [10,13].”
Perlin, D. S., & Wiederhold, N. P. (2017) · The Journal of Infectious Diseases · doi:10.1093/infdis/jix121 · Cited by 49
Senchyna, F., Hogan, C. A., Murugesan, K., Moreno, Á., Ho, D. Y., Subramanian, A. K., Schwenk, H. T., Budvytiene, I., Costa, H. A., Gombar, S., et al. (2021) · Clinical Infectious Diseases · doi:10.1093/cid/ciab158 · Cited by 53
Diagnosis of Invasive Candidiasis: From Gold Standard Methods to Promising Leading-edge Technologies
Pitarch, A., Nombela, C., & Gil, C. (2018) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026618666181025093146 · Cited by 56
“Lamentably, this slow turnaround time leads to delayed therapeutic interventions with ensuing poor outcomes of IC patients [37].”
BackgroundInfluentialNgamchokwathana, C., Chongtrakool, P., Waesamaae, A., & Chayakulkeeree, M. (2021) · Journal of Fungi · doi:10.3390/jof7040269 · Cited by 52
“Delay in the initiation of fluconazole therapy in hospitalized patients with candidemia significantly adversely influenced mortality [18].”
BackgroundImpact of tolerance to fluconazole on treatment response in Candida albicans bloodstream infection
Levinson, T., Dahan, A., Novikov, A., Paran, Y., Berman, J., & Ben‐Ami, R. (2021) · Mycoses · doi:10.1111/myc.13191 · Cited by 50
How much European prescribing physicians know about invasive fungal infections management?
Valerio, M., Vena, A., Bouza, E., Reiter, N., Viale, P., Hochreiter, M., Giannella, M., Muñóz, P., & on behalf the COMIC study group (Collaborative group on Mycosis) (2015) · BMC Infectious Diseases · doi:10.1186/s12879-015-0809-z · Cited by 53
“However, the clinical outcome in IFI related sepsis is not only related to adequacy and timeliness of antifungal administration, but also on appropriate dosing, all these factors associated with length of hospital stay, health care costs, morbidity and mortality [20,22,24].”
BackgroundMortality in patients with early- or late-onset candidaemia
Rosa, F. G. D., Trecarichi, E. M., Montrucchio, C., Losito, A. R., Raviolo, S., Posteraro, B., Corcione, S., Giambenedetto, S. D., Fossati, L., Sanguinetti, M., et al. (2012) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dks480 · Cited by 55
Comparison of albicans vs. non-albicans candidemia in French intensive care units
Leroy, O., Mira, J.-P., Montravers, P., Gangneux, J.-P., Lortholary, O., & the AmarCand Study Group (2010) · Critical Care · doi:10.1186/cc9033 · Cited by 47
“The relationship between prognosis and early initiation of the adequate antifungal therapy is well established [2-4].”
BackgroundCandidemia and invasive candidiasis among hospitalized neonates and pediatric patients
Harrington, R., Kindermann, S. L., Hou, Q., Taylor, R. J., Azie, N., & Horn, D. L. (2017) · Current Medical Research and Opinion · doi:10.1080/03007995.2017.1354824 · Cited by 47
T2 Magnetic Resonance Assay: Overview of Available Data and Clinical Implications
Zacharioudakis, I. M., Zervou, F. N., & Mylonakis, E. E. (2018) · Journal of Fungi · doi:10.3390/jof4020045 · Cited by 50
Rautemaa‐Richardson, R., Rautemaa, V., Al-Wathiqi, F., Moore, C. B., Craig, L., Felton, T., & Muldoon, E. G. (2018) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dky360 · Cited by 53
Metadata
- Authors
- Garey, K. W., Rege, M., Pai, M. P., Mingo, D. E., Suda, K. J., Turpin, R. S., & Bearden, D. T.
- Affiliations
- University of Houston (US)
- University of New Mexico (US)
- Baptist Memorial Health Care (US)
- University of Tennessee Health Science Center (US)
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- Oregon State University (US)
- Corresponding author
- Garey, Kevin W.
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2006-07
- Volume
- 43
- Issue
- 1
- Pages
- 25-31
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- OpenAlex
- W2164001967
- Semantic Scholar
- e1a67fd5e540307550577ea7a071370b075e943f
- Cited by
- 1,171
- References
- 20
- Citations by year
- 2026: 31 · 2025: 26 · 2024: 31 · 2023: 31 · 2022: 49 · 2021: 67 · 2020: 51 · 2019: 51 · 2018: 62 · 2017: 66 · 2016: 61 · 2015: 74 · 2014: 87 · 2013: 83 · 2012: 77
- FWCI
- 35.06
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Clinical Infectious Diseases (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Enzon Pharmaceuticals
- University of Houston
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Infective Endocarditis Diagnosis and Management
- Health Sciences › Medicine › Infectious Diseases › Fungal Infections and Studies
- Keywords
- candidemia, fluconazole, treatment delay, mortality, fungemia, Candida albicans, APACHE II score, mortality risk factors, hospitalized patients, Candida tropicalis, Candida parapsilosis, Candida glabrata, diabetes mellitus, cancer patients, sepsis
- MeSH terms
- Adult, Aged, Antifungal Agents, Candidiasis, Female, Humans, Length of Stay, Male, Middle Aged, Retrospective Studies, Time Factors, Cohort Studies, Fluconazole, Fungemia
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.